# US 6,720,005 B1 · Coated, platform-generating tablet > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,720,005 B1 - Document ID: US6720005B1 - Status: Granted - Kind: B1 - Application number: 09/887,318 - Filed: 2001-06-21 - Granted: 2004-04-13 - Earliest claimed: 2000-07-07 - Assignees: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University - Inventors: James W. Ayres - Web page: https://patentgrep.com/patent/US6720005B1 ## CPC - A61K 9/2846: {Poly(meth)acrylates} - A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)} - A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract An expanding tablet is described comprising a drug release controlling membrane material. After swallowing, the tablet hydrates and expands such that the membrane ruptures to directly expose some surfaces of the core tablet to hydrating and eroding liquids, thus generating in situ a tablet which is platform supported on non-exposed surfaces, and which releases active ingredient in approximately zero order fashion. More particularly, the dosage form is adapted for controlled release of various pharmaceuticals. A working embodiment of the tablet was a spray-coated tablet comprising a core having greater than 25% of an expandable material which expands upon exposure to an aqueous environment and at least one active ingredient, e.g., glipizide, and an outer rupturable coating surrounding the core comprising a rate release modifying membrane and a water-soluble modifier. A method for administering an active ingredient also is described. The method comprises (1) providing a tablet according to the invention, and (2) administering the tablet to a patient. ## Claims ### Claim 1 A sustained release tablet, comprising: a swellable core, the core made from core materials comprising (a) at least one active ingredient, and (b) a mixture of expandable materials, or greater than 25% by weight of an expandable material based upon total core weight, the expandable material or materials expanding upon exposure to an aqueous environment, the core materials defining a belly band comprising the at least one active ingredient; and an outer rupturable coating surrounding the core, the coating rupturing in a subject's gastrointestinal tract, and comprising a rate release modifying membrane and a water-soluble modifier. ### Claim 2 (depends on 1) The tablet according to claim 1 where the core comprises at least one hydrophilic gum material. ### Claim 3 (depends on 1) The tablet according to claim 1 further comprising an over coating of an active ingredient. ### Claim 4 (depends on 1) The tablet according to claim 1 where at least a portion of the coating ruptures adjacent to or in the belly band upon exposure to an aqueous fluid. ### Claim 5 (depends on 4) The tablet according to claim 4 which produces a support platform for drug delivery. ### Claim 6 (depends on 1) The tablet according to claim 1 where the rate release modifying membrane contains one or more active ingredients. ### Claim 7 (depends on 1) The tablet according to claim 1 comprising pectin. ### Claim 8 (depends on 7) The tablet according to claim 7 where the pectin is low methoxy pectin. ### Claim 9 (depends on 1) The tablet according to claim 1 where the expandable material is an expanding hydrophilic gum or mixture of hydrophilic gums. ### Claim 10 (depends on 1) The tablet according to claim 1 where the rate release modifying membrane is ethyl cellulose or a methacrylate polymer containing modifiers which influence active ingredient release. ### Claim 11 (depends on 4) The tablet according to claim 4 where the belly band is the primary area exposed directly to hydrating fluids by rupture of the rate release modifying membrane. ### Claim 12 (depends on 4) The tablet according to claim 4 where the belly band area is from 0.1 to 1.0 of the tablet height measured at the tallest point. ### Claim 13 (depends on 1) The tablet according to claim 1 where the rate release modifying membrane is over coated or undercoated with an enteric coating material. ### Claim 14 (depends on 1) The tablet according to claim 1 where sustained release of an active ingredient following a lag time is sufficient to provide therapeutically effective active ingredient concentrations when administered in a once- or twice-daily dosing regimen. ### Claim 15 (depends on 1) The tablet according to claim 1 where dissolution of an active ingredient measured in vitro in a USP paddle stirring apparatus in appropriate aqueous media at 37° C., substantially corresponds to the following: from 0 to 5% of the total active ingredient is released after one hour, from 5 to 40% of the total active ingredient is released after four hours; from 10 to 80% of the total active ingredient is released after eight hours; and not less than 70% of the total active ingredient is released in 24 hours. ### Claim 16 (depends on 15) The tablet according to claim 15 having an active ingredient dissolution lag time, and having an n value of 0.7 or more from time of 10% active ingredient released until time of 75% active ingredient released. ### Claim 17 (depends on 16) The tablet according to claim 16 having an n value of 0.85 or more from time of 10% active ingredient released until time of 85% active ingredient released. ### Claim 18 (depends on 1) The tablet according to claim 1 comprising a mixture of hydrophilic gum polymers, at least one of which is modified by enzymes in the intestinal tract. ### Claim 19 (depends on 1) The tablet according to claim 1 having a drug-delivery lag time of from about 0.5 hours or more and less than or equal to about 6 hours. ### Claim 20 (depends on 1) The tablet according to claim 1 having a drug delivery lag time of from about 1 to about 3 hours. ### Claim 21 (depends on 18) The tablet according to claim 18 where the hydrophilic gum polymer modified by enzymes in the intestinal tract is pectin. ### Claim 22 (depends on 1) The tablet according to claim 1 where the rate release modifying membrane is ethyl cellulose or a methacrylate polymer. ### Claim 23 (depends on 4) The tablet according to claim 4 where the belly band is between 1 and 8 mm thick and the length of the tablet is at least 8 mm. ### Claim 24 (depends on 4) The tablet according to claim 4 where the belly band is equal to or larger than a vertical height of the tablet as measured at a center portion of the tablet. ### Claim 25 (depends on 4) The tablet according to claim 4 where the rate release modifying membrane has been over coated with one or more active ingredients which may or may not exhibit a lag time for active ingredient dissolution. ### Claim 26 (depends on 1) The tablet according to claim 1 where calculated n value for average dissolution results after a lag time is greater than at least 0.70 from time of 10% active ingredient released until time of 75% active ingredient released. ### Claim 27 (depends on 1) The tablet according to claim 1 where calculated n value for average dissolution results after a lag time is greater than at least 0.85 from time of 5% active ingredient released until time of 85% ingredient released. ### Claim 28 (depends on 1) The tablet according to claim 1 where the active ingredient is glipizide. ### Claim 29 (depends on 1) A spray-coated tablet according to claim 1. ### Claim 30 (depends on 3) The tablet according to claim 3 where dissolution of active ingredient from the over coating and dissolution of active ingredient from a coated hydrophilic gum matrix core tablet is approximately zero order in that a calculated n value for average dissolution is greater than 0.70 from time of 10% active ingredient released until time of 75% active ingredient released. ### Claim 31 (depends on 3) The tablet according to claim 3 where dissolution of active ingredient from a coated hydrophilic gum matrix core tablet is approximately zero order, independent of active ingredient release from the over coating, in that a calculated n value for average dissolution from the coated core is greater than 0.70 from time of 10% active ingredient released until time of 75% active ingredient released. ### Claim 32 (depends on 3) The tablet according to claim 3 where dissolution of the active ingredient from the over coating plus dissolution of active ingredient from a coated hydrophilic gum matrix core tablet is approximately zero order in that a calculated n value for average dissolution result is greater than 0.85 from time of 5% active ingredient released until time of 85% active ingredient released. ### Claim 33 (depends on 3) The tablet according to claim 3 where dissolution of the active ingredient from a coated core tablet is approximately zero order, independent of active ingredient release from the overcoating, in that a calculated n value for average dissolution result from the coated core is greater than 0.85 from time of 5% active ingredient released until time of 85% active ingredient released. ### Claim 34 (depends on 3) The tablet according to claim 3 wherein there is a burst dissolution of active ingredient(s) from the over coating, and then a calculated n value for average dissolution results for at least one active ingredient released from a coated core tablet after a lag time is greater than at least 0.70 from time of 10% release of the active ingredient in the core tablet is released until time of 75% of the active ingredient in the core tablet is released. ### Claim 35 (depends on 1) The tablet of claim 1 where, during hydration with aqueous fluids, the swellable core swells and ruptures the rate controlling membrane which breaks away from part of the tablet and exposes portions of the core tablet, and remains attached to portions of the tablet providing a support platform for at least two hours after initial breaking of the polymer release rate controlling film. ### Claim 36 (depends on 33) The tablet of claim 33 where, during hydration with aqueous fluids, the swellable core swells and ruptures the rate controlling membrane which breaks away from part of the tablet and exposes portions of the hydrophilic gum polymer core tablet, and remains attached to portions of the tablet providing a support platform for at least two hours after initial breaking of the polymer release rate controlling film occurs. ### Claim 37 A method for administering an active ingredient, comprising: providing a tablet comprising a core having an active ingredient and an expandable material that expands upon exposure to aqueous environment, the core surrounded by an outer rate release modifying membrane that ruptures in a subject's gastrointestinal tract, the tablet having a belly band comprising the active ingredient; and administering the tablet to the subject. ### Claim 38 A method for administering an active ingredient, comprising: providing a tablet, the tablet comprising a core comprising an active ingredient and an expandable material that expands upon exposure to an aqueous environment, an outer rupturable rate release modifying membrane, that ruptures in a subject's gastrointestinal tract, the tablet providing active ingredient release over at least a 16-hour period, and a belly band comprising the active ingredient; and administering the tablet to the subject. ### Claim 39 (depends on 38) The method according to claim 38 where the expandable material is enzymatically modifiable. ### Claim 40 (depends on 1) The tablet according to claim 1 where the outer rupturable coating includes a water insoluble modifier. ### Claim 41 A tablet, comprising: a core having at least one active ingredient, a mixture of expandable materials, or greater than 25% by weight of an expandable material based upon total core weight, the expandable material or materials expanding upon exposure to an aqueous environment, and a belly band comprising the at least one active ingredient; and an outer rupturable coating surrounding the core that ruptures in a subject's gastrointestinal tract, the coating comprising a rate release modifying membrane and a film modifier. ### Claim 42 (depends on 41) The tablet according to claim 41 where the rate release modifying membrane is ethyl cellulose or a methacrylate polymer containing modifiers which influence active ingredient release. ### Claim 43 A method for administering an active ingredient, comprising: providing a tablet which exhibits a lag time for active ingredient dissolution from a core, the tablet comprising a core having an expandable material which expands upon exposure to an aqueous environment, at least one active ingredient, a belly band comprising the at least one active ingredient and an outer rupturable coating surrounding the core comprising a rate release modifying membrane and a film modifier; and administering the tablet to a subject, the tablet thereafter undergoing hydration so that, during hydration of the tablet, the core swells and ruptures the rate release modifying membrane in a subject's gastrointestinal tract, which breaks away from part of the tablet and exposed portions of the core, and remains attached to portions of the tablet providing a support platform for at least two hours when tested in vitro after initial rupture of the rate release modifying membrane occurs. ### Claim 44 (depends on 15) The tablet according to claim 15 where from 20 to 80% of the total active ingredient is released after eight hours. ### Claim 45 (depends on 15) The tablet according to claim 15 where not less than 80% of the total active ingredient is released in 24 hours. ### Claim 46 A tablet, comprising: a core having at least one active ingredient, a mixture of expandable materials, or greater than 25% by weight of an expandable material based upon total core weight, the expandable material or materials expanding upon exposure to an aqueous environment, and a belly band comprising the at least one active ingredient; an outer rupturable coating that ruptures in a subject's gastrointestinal tract; and an over coating comprising at least one active ingredient. ### Claim 47 A tablet, comprising: a core having at least one active ingredient, and a mixture of expandable materials, or greater than 25% by weight of an expandable material based upon total core weight, the expandable material or materials expanding upon exposure to an aqueous environment, and a belly band comprising the at least one active ingredient; and an outer rupturable coating that ruptures in a subject's gastrointestinal tract. ### Claim 48 A tablet, comprising a core having at least one active ingredient, a mixture of expandable materials, or greater than 25% by weight of an expandable material based upon total core weight, the expandable material or materials expanding upon exposure to an aqueous environment, and a belly band comprising the at least one active ingredient, where dissolution of the active ingredient is approximately zero order following an active ingredient dissolution lag time of from about 0.5 hour to about 6 hours.